Skip to market wire
InvestLog
← Back to Stock Events← 返回个股快讯
INSMEarnings Release财报快讯Media source媒体来源Source link原始来源by InvestLog AIInvestLog AI 整理
Event time: 事件时间：
Published: 文章发布：

INSM earnings release — EPS missed · revenue beat +4.8%Insmed, Inc. (INSM) 财报发布 — EPS 低于预期 · 营收 高于预期+4.8%

Key Results

Actual vs Consensus

  • EPS: -$0.46 vs -$0.38 estimate, missed.
  • Revenue: $524M vs $500M estimate, beat+4.8%.

    • Profitability and Cash Flow

  • Period: 2026 Q3 period ended 2026-09-30
  • Revenue: $524M; YoY: +268.4%; QoQ: +23.3%
  • Gross profit: $446M; Gross margin: 85.1%
  • Operating income: -$89M; Operating margin: -17.0%
  • Net income: -$100M; GAAP diluted EPS: -$0.46
  • Operating cash flow: -$36M; Capex: $6M; Free cash flow: -$42M
  • Cash: $397M; Total debt: $40M; Net cash: $357M

    • Official release: Insmed Reports Third-Quarter 2026 Financial Results and Provides Business Update

    核心结果

    实际值与市场预期

  • EPS：-$0.46 vs -$0.38 预期，低于预期。
  • 营收：$524M vs $500M 预期，高于预期+4.8%。

    • 财务指标

  • 期间：2026 Q3（截至 2026-09-30）
  • 营收：$524M；同比：+268.4%；环比：+23.3%
  • 毛利润：$446M；毛利率：85.1%
  • 经营利润：-$89M；经营利润率：-17.0%
  • 净利润：-$100M；GAAP 稀释 EPS：-$0.46
  • 经营现金流：-$36M；资本开支：$6M；自由现金流：-$42M
  • 现金：$397M；总债务：$40M；净现金：$357M
    • View INSM stock details ->查看 INSM 个股详情 ->

    For information only. Not investment advice.内容仅供参考，不构成投资建议。

    Related articles相关阅读

    Barclays lowers INSM target to $207 from $237Barclays 下调目标价 INSM：$237 → $207

    Rating Change · September 30, 2026评级变动 · 2026/9/30

    INSM regulatory decision: FDA Grants Priority Review to Insmed's sNDA for ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of MAC Lung Disease With PDUFA Target Action Date Set for January 28, 2027Insmed Incorporated（INSM）披露重大监管决定

    Material Company Event · September 21, 2026公司公告 · 2026/9/21

    Adsett Roger sells $32.0M of INSMAdsett Roger 内部减持 INSM $32.0M

    Insider Sale · August 12, 2026内部人减持 · 2026/8/12